Loading
companiesCompany
HotSpot Therapeutics
HotSpot Therapeutics is a Boston biotech that drugs the regulatory pockets of proteins rather than their active sites; its oral CBL-B inhibitor HST-1011 releases a brake on T cells.
Also called: HotSpot Therapeutics, Inc.
Overview
HotSpot Therapeutics targets natural regulatory hotspots, allosteric sites that control protein function, using its Smart Allostery platform. Its first clinical candidate HST-1011 is an oral allosteric inhibitor of the E3 ubiquitin ligase CBL-B, an intracellular checkpoint that limits T-cell and natural killer cell activation. HST-1011 is in a phase 1/2 trial alone and with cemiplimab in advanced solid tumours; the company also develops an IRF5 inhibitor for autoimmune disease.
Headquarters
Boston, Massachusetts, US
Scorecard
All companies#480of 1244 companies, score 5
- phase 1/2 +1
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Website
Founded
2017
Phase 2Small-molecule inhibitor
HST-1011 is a small-molecule inhibitor from HotSpot Therapeutics, Inc, in registered phase 2 trials for metastatic cancer.
drugs
Phase 2Small-molecule inhibitor